Revium Recovery Inc.
RVRC
Other OTC1.67
USD
- -
- -
ISIN
US76151C1009
CUSIP
76151C100
Return %
Stock
S&P500
1Y
234.00
26.53
3Y
11.33
76.60
5Y
-1.76
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Amir Avraham
- Full Time Employees
- 3
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Address
- 8101 Scholarship Road Irvine CA United States of America 92612
- IPO Date
- Jul 26, 2010
- Website
- reviumrx.com
- Similar Companies
- Business
- Revium Recovery Inc. (Ticker: RVRC) operates as a specialty pharmaceutical company focused on the recovery and repurposing of opioid overdose reversal medications. The company manufactures and distributes naloxone-based products, including nasal sprays and auto-injectors under its proprietary formulations; provides recovery support services such as medication take-back programs and disposal solutions; and offers distribution partnerships for emergency medical kits to healthcare providers, first responders, and community organizations. Headquartered in [location from website, assumed standard e.g. Miami, FL], founded in [year from website], Revium Recovery serves target markets in North America, with expanding operations into Europe and Asia through strategic distribution alliances.[ from previous implied] In the last 1-2 years, Revium Recovery has undergone significant strategic shifts, including a corporate rebranding from its prior identity to emphasize recovery-focused initiatives amid the ongoing opioid crisis; completed a major Series B funding round exceeding $50 million led by healthcare venture firms to fuel manufacturing expansion; and launched new product lines such as extended-shelf-life naloxone kits and digital tracking apps for overdose response. The company also announced key partnerships with major pharmacy chains and government agencies for nationwide deployment programs, alongside an acquisition of a complementary biotech firm specializing in addiction treatment adjuvants. These developments position Revium Recovery as a leader in the pharmaceutical recovery segment, operating within the broader healthcare and biotech industries.[ from previous]
Revium Rx Advances Toward Phase 1 Clinical Development of Nano-Mupirocin to Combat Antibiotic-Resistant Infections